- Email: [email protected]
Drugs Affecting Lipid Metabolism. Edited by R. Paoletti, D. Kritchevsky, and W. L. Holmes. Springer-Verlag: New York. 1987. xvi + 451 pp. 25 × 17 cm. ISBN 3-540-17277-7. $76.50
BOOK REVIEWS including hypolipidemic agents, environmental agents, enTablet Machine Instrumentcttion in Pharmaceutics: Princizyme inducers, steroids, and alpha- and beta-blocking agents, ples and Practice. By Peter Ridgway Watt. John Wiley: New York. 1988. 346 pp. 24.5 x 17 cm. ISBN 0470-21088-5. and by phospholipids; (5) dietary effects on lipid metabolism
$69.95. This book is a volume in the series Pharmaceutical Technology, edited by M. H. Rubinstein. The book is a good primer for a novice unfamiliar with the actual instrument of single punch and rotating tablet presses, and is divided into two parts: “Principles” and “Practice”. The first part deals with the measurement of force, displacement, and temperature, as well as methods and equipment for data handling. Four chapters are devoted to theory and operation of strain gauges. The material covered suggests suitable alternatives to strain gauges. The author fails to cover why each measurement is necessary. The second part deals with the measurement of punch forces, die wall stress, displacement, temperature, tablet weight, and post-compressionalmeasurements. Additionally, calibration of transducer systems and interpretation of the data collected is covered. This part features impressive work on the application of holography, optical scanning, and acoustic emission to studies in tablet instrumentation. Instrumentation supplied by each press manufacturer and advantages andlor disadvantages are discussed in depth. However, case studies of actual use of insti*umentation in the pharmaceutical industry are missing. Overall, the book is excellent in presentation, with thorough coverage of references. This valuable book should serve as a useful source for graduate students, scientists, and industrial personnel dealing with the instrumentation, formulation research, and prolduction of tablet dosage forms. Praveen Tyle and David Bogan Sandoz Pharmaceuticals Corporation Lincoln, NE 68501
Drugs Affecting Lipid Metmabolism.Edited by R. Paoletti, D. Kritchevsky, and W. L. Holmes. Springer-Verlag: New York. 1987.xvi f 451 pp. 25 x 17cm. ISBN3-540-17277-7.$76.50. This text is a collection of papers based on the presentation of the meeting on “Drugs Affecting Lipid Metabolism” held in Florence, Italy, October 22-25, 1986. This volume includes
the contributions of many laboratories and workers in the field of lipid metabolism from Japan, Europe, and the United States. Topics range from clinical studies on new hypolipidemic agents to rather esoteric biochemical relationships between cholesterol levels and DNA synthesis o f normal and cancerous cells. Nevertheless, the foci of the several chapters were as follows: (1)regulation of alcyl CoA cholesterol acyl transferase, cholesterol-7-a hydroxylase, HMG-CoA reductase, hormone-sensitive lipase, and hepatic lipase with emphasis on phosphorylation and dephosphorylation of enzyme subunits; (2) transport of cholesterol by HDL, composition of the lipoprotein, reverse transport of cholesterol, relationship of cholesterol with LCAT, lipid transfer protein, lipoprotein lipase, receptor mediated uptake, and transport of cholesterol; (3) correlation of HDL apo A-I and apo Ad1 metabolism and the incidence of coronary heart disease in man; (4)modulation of HDL structure, lipid content, and metabolism by drugs, 0022-3549/89/1200-1057$01.OO/O 0 7989, American Pharmaceutical Association
by fish oil, peanut oil, cocoa butter, soybean protein, tocopherol, mono-saturated and omega-3-polyunsaturated fatty acids, linoleic acids, and arachidonic acids; (6)correlation of bile acid synthesis with the effects of terpenes, gemfibrozil, clofibrate, and treatment with bile sequestrants as well as with its relationship to LDL receptor synthesis and HMGCoA reductase inhibitors; (7) investigation of gene regulation and genetic markers for inherited hyperlipidemic states, for apoproteins A-IIC-111, and for apoprotein B-100; (8) compilations of clinical studies, long-term studies, distribution studies, adverse and side effects, mechanism of action, tissue culture studies, and lipoprotein apoprotein and lipid analysis after treatment with probucol, compactin, lovastatin, CS-514, bezafibrate, fenofibrate, gemfibrozil, etofibrate, lipanthyl, nicotinic acid derivatives L-44, and pantethine; (9) evaluation of hyperlipidemic agents on platelet function and aggregability and its relationship to atherosclerosis; (10) relationship of fatty acid binding protein t o lipid metabolism after treatment with hyperlipidemic agents. Additional discussions were related more to the scientific merits of the design of experimental studies, including: (1)an animal model for atherosclerosis when examining hypolipidemic drugs; (2) record monitoring of clinical studies of experimental hyperlipidemic agents; and (3) selection of which parameter to measure in lipoprotein metabolism during clinical trials of agents. These individual short chapters are well written, illustrated, and referenced through 1986. The book presents basic concepts and is accurate in its scientific content, but cursory in scope. This volume does serve to accumulate diverse discussions in the area of lipid metabolism. However, it did not extend to experimental agents which are not, to date, in clinical trials. The clinical data presented in many of the papers were not subjected to statistical analysis which certainly would have improved the credibility of the research. This is a monograph that I recommend t o any student in lipid metabolism, particularly beginning graduate students and post-doctoral fellows studying in this challenging area. The format of the book does not lend itself for use as a textbook for a class, but it is an excellent reference book which should be in any Health Science Affairs library for pharmaceutical scientists.
Iris H. Hall
School of Pharmacy University of North Carolina Chapel Hill, NC 27599
Clinical Drug Trials and Tribulations. Edited by Allen E. Cato. Marcel Dekker: New York. 1988. xiii + 432 pp. ISBN 08247-7854-5. 16 x 23 cm. $125.00.
This text is designed as a guide to the problems and rewards of clinical drug development. Rather than providing a “How to” for clinical trials, this book offers the reader a perspective on drug development and the reasons behind the decisions associated with the development process. The volume covers a number of topics regarding drug Journal of Pharmaceutical Sciences I 1057 Voi. 78, No. 12,December 7989
$69.95. This book is a volume in the series Pharmaceutical Technology, edited by M. H. Rubinstein. The book is a good primer for a novice unfamiliar with the actual instrument of single punch and rotating tablet presses, and is divided into two parts: “Principles” and “Practice”. The first part deals with the measurement of force, displacement, and temperature, as well as methods and equipment for data handling. Four chapters are devoted to theory and operation of strain gauges. The material covered suggests suitable alternatives to strain gauges. The author fails to cover why each measurement is necessary. The second part deals with the measurement of punch forces, die wall stress, displacement, temperature, tablet weight, and post-compressionalmeasurements. Additionally, calibration of transducer systems and interpretation of the data collected is covered. This part features impressive work on the application of holography, optical scanning, and acoustic emission to studies in tablet instrumentation. Instrumentation supplied by each press manufacturer and advantages andlor disadvantages are discussed in depth. However, case studies of actual use of insti*umentation in the pharmaceutical industry are missing. Overall, the book is excellent in presentation, with thorough coverage of references. This valuable book should serve as a useful source for graduate students, scientists, and industrial personnel dealing with the instrumentation, formulation research, and prolduction of tablet dosage forms. Praveen Tyle and David Bogan Sandoz Pharmaceuticals Corporation Lincoln, NE 68501
Drugs Affecting Lipid Metmabolism.Edited by R. Paoletti, D. Kritchevsky, and W. L. Holmes. Springer-Verlag: New York. 1987.xvi f 451 pp. 25 x 17cm. ISBN3-540-17277-7.$76.50. This text is a collection of papers based on the presentation of the meeting on “Drugs Affecting Lipid Metabolism” held in Florence, Italy, October 22-25, 1986. This volume includes
the contributions of many laboratories and workers in the field of lipid metabolism from Japan, Europe, and the United States. Topics range from clinical studies on new hypolipidemic agents to rather esoteric biochemical relationships between cholesterol levels and DNA synthesis o f normal and cancerous cells. Nevertheless, the foci of the several chapters were as follows: (1)regulation of alcyl CoA cholesterol acyl transferase, cholesterol-7-a hydroxylase, HMG-CoA reductase, hormone-sensitive lipase, and hepatic lipase with emphasis on phosphorylation and dephosphorylation of enzyme subunits; (2) transport of cholesterol by HDL, composition of the lipoprotein, reverse transport of cholesterol, relationship of cholesterol with LCAT, lipid transfer protein, lipoprotein lipase, receptor mediated uptake, and transport of cholesterol; (3) correlation of HDL apo A-I and apo Ad1 metabolism and the incidence of coronary heart disease in man; (4)modulation of HDL structure, lipid content, and metabolism by drugs, 0022-3549/89/1200-1057$01.OO/O 0 7989, American Pharmaceutical Association
by fish oil, peanut oil, cocoa butter, soybean protein, tocopherol, mono-saturated and omega-3-polyunsaturated fatty acids, linoleic acids, and arachidonic acids; (6)correlation of bile acid synthesis with the effects of terpenes, gemfibrozil, clofibrate, and treatment with bile sequestrants as well as with its relationship to LDL receptor synthesis and HMGCoA reductase inhibitors; (7) investigation of gene regulation and genetic markers for inherited hyperlipidemic states, for apoproteins A-IIC-111, and for apoprotein B-100; (8) compilations of clinical studies, long-term studies, distribution studies, adverse and side effects, mechanism of action, tissue culture studies, and lipoprotein apoprotein and lipid analysis after treatment with probucol, compactin, lovastatin, CS-514, bezafibrate, fenofibrate, gemfibrozil, etofibrate, lipanthyl, nicotinic acid derivatives L-44, and pantethine; (9) evaluation of hyperlipidemic agents on platelet function and aggregability and its relationship to atherosclerosis; (10) relationship of fatty acid binding protein t o lipid metabolism after treatment with hyperlipidemic agents. Additional discussions were related more to the scientific merits of the design of experimental studies, including: (1)an animal model for atherosclerosis when examining hypolipidemic drugs; (2) record monitoring of clinical studies of experimental hyperlipidemic agents; and (3) selection of which parameter to measure in lipoprotein metabolism during clinical trials of agents. These individual short chapters are well written, illustrated, and referenced through 1986. The book presents basic concepts and is accurate in its scientific content, but cursory in scope. This volume does serve to accumulate diverse discussions in the area of lipid metabolism. However, it did not extend to experimental agents which are not, to date, in clinical trials. The clinical data presented in many of the papers were not subjected to statistical analysis which certainly would have improved the credibility of the research. This is a monograph that I recommend t o any student in lipid metabolism, particularly beginning graduate students and post-doctoral fellows studying in this challenging area. The format of the book does not lend itself for use as a textbook for a class, but it is an excellent reference book which should be in any Health Science Affairs library for pharmaceutical scientists.
Iris H. Hall
School of Pharmacy University of North Carolina Chapel Hill, NC 27599
Clinical Drug Trials and Tribulations. Edited by Allen E. Cato. Marcel Dekker: New York. 1988. xiii + 432 pp. ISBN 08247-7854-5. 16 x 23 cm. $125.00.
This text is designed as a guide to the problems and rewards of clinical drug development. Rather than providing a “How to” for clinical trials, this book offers the reader a perspective on drug development and the reasons behind the decisions associated with the development process. The volume covers a number of topics regarding drug Journal of Pharmaceutical Sciences I 1057 Voi. 78, No. 12,December 7989